NYSE · ABT
Abbott Laboratories
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
Loading market information…
NYSE · BDX · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Becton, Dickinson and Company’s quoted price sits in the upper half of its reported 52-week range, 1.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Becton, Dickinson and Company’s forward annual dividend is $4.20 per share, paid quarterly. The forward yield is 2.12% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Becton, Dickinson and Company’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $4.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Becton, Dickinson and Company’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | May 1, 2025 | $3.35+2.13% vs estimate | $5.27B-1.51% vs estimate |
|---|
| Q1 2025 | Feb 5, 2025 | $3.43+14.33% vs estimate | $5.17B+1.33% vs estimate |
|---|
| Q4 2024 | Nov 7, 2024 | $3.81+1.06% vs estimate | $5.44B+1.06% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
34 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $190.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$416.67+$13.03 (+3.23%)
West Pharmaceutical Services, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.93% below the high.
$83.56+$1.71 (+2.09%)
Solventum Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.26% below the high.
$23.50-$1.96 (-7.7%)
Baxter International Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.67% below the high.
$141.39+$2.41 (+1.73%)
Teleflex Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.49% below the high.
$93.39+$1.18 (+1.28%)
Merit Medical Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.66% below the high.
$168.65+$2.26 (+1.36%)
ICU Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.55% below the high.
